Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Imfinzi (durvalumab)
Pharma
AZ's Imfinzi keeps MIBC race against Keytruda hot with FDA nod
AstraZeneca has crossed the finish line in MIBC with its own doublet wedding Pfizer and Astellas’ Padcev with its PD-L1 inhibitor Imfinzi.
Fraiser Kansteiner
Nov 13, 2026 5:40pm
Akeso CEO looks for more ivonescimab combos after AZ deal
Oct 25, 2026 11:30am
ESMO: AstraZeneca pitches own Padcev combos in bladder cancer
Oct 24, 2026 10:30am
ESMO: Amgen’s Imdelltra stages Rasonque-like moment in SCLC
Oct 24, 2026 10:30am
Amgen’s Imdelltra scores overall survival win in first-line SCLC
Sep 8, 2026 11:42am
FDA expands Padcev-Keytruda combo to more MIBC patients
Jul 10, 2026 1:10pm